[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse B3GNT3

Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Single-pass type II membrane protein
Domain PF01762 Galactosyltransferase
Function

Beta-1,3-N-acetylglucosaminyltransferase involved in the synthesis of poly-N-acetyllactosamine. Has activity for type 2 oligosaccharides (PubMed:11042166). Also acts as a core1-1,3-N-acetylglucosaminyltransferase (Core1-beta3GlcNAcT) to form the 6-sulfo sialyl Lewis x on extended core1 O-glycans (PubMed:11439191).

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0005976 polysaccharide metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0006790 sulfur compound metabolic process
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016051 carbohydrate biosynthetic process
GO:0016266 O-glycan processing
GO:0018146 keratan sulfate biosynthetic process
GO:0030203 glycosaminoglycan metabolic process
GO:0030309 poly-N-acetyllactosamine metabolic process
GO:0030311 poly-N-acetyllactosamine biosynthetic process
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0042339 keratan sulfate metabolic process
GO:0043413 macromolecule glycosylation
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044272 sulfur compound biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0070085 glycosylation
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0008194 UDP-glycosyltransferase activity
GO:0008375 acetylglucosaminyltransferase activity
GO:0008378 galactosyltransferase activity
GO:0008499 UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity
GO:0008532 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
GO:0035250 UDP-galactosyltransferase activity
GO:0047223 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity
GO:0048531 beta-1,3-galactosyltransferase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series
hsa01100 Metabolic pathways
Reactome R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022854: Keratan sulfate biosynthesis
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between B3GNT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between B3GNT3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29438695Triple-Negative Breast CarcinomaInhibit immunityDownregulation of B3GNT3 enhances cytotoxic T cell-mediated anti-tumor immunity.
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of B3GNT3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of B3GNT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1210.615
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2210.654
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3760.398
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6730.368
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4370.802
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9580.61
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4660.599
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2340.358
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.350.809
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6820.633
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9270.636
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2560.297
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of B3GNT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of B3GNT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of B3GNT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by B3GNT3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of B3GNT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of B3GNT3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between B3GNT3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolB3GNT3
NameUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3
Aliases B3GN-T3; beta3Gn-T3; HP10328; B3GNT-3; putative type II membrane protein; beta-1,3-N-acetylglucosaminyltrans ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting B3GNT3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.